Related Experiment Video
Updated: Aug 6, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
A 59-year-old woman with refractory uveitis
Lisa R Koenig1, Eli L Diamond2, Jasmine H Francis1
1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Retinal Cases & Brief Reports
|July 21, 2026
Summary
Ophthalmic artery chemosurgery (OAC) with melphalan offers a novel and durable treatment for refractory Rosai-Dorfman-Destombes disease (RDD) of the eye. This approach led to sustained resolution of ophthalmic manifestations and maintained visual acuity over four years.
Area of Science:
- Ophthalmology
- Oncology
- Dermatology
Background:
- Histiocytosis, particularly Rosai-Dorfman-Destombes disease (RDD), can present with challenging ophthalmic manifestations.
- Refractory cases require innovative treatment strategies to preserve vision and ocular health.
Purpose of the Study:
- To report a novel application of melphalan delivered via ophthalmic artery chemosurgery (OAC).
- To evaluate the long-term efficacy and durability of this treatment for ophthalmic RDD.
Main Methods:
- A case report detailing the treatment of a patient with RDD.
- Administration of cobimetinib and melphalan via OAC for refractory ophthalmic symptoms.
Main Results:
- Successful treatment of RDD presenting as refractory anterior uveitis and nodular scleritis.
- Complete resolution of ophthalmic manifestations maintained for four years.
- Visual acuity remained excellent (20/20) at the four-year follow-up.
Conclusions:
- Ophthalmic artery chemosurgery (OAC) with melphalan is a novel and effective treatment for ophthalmic RDD.
- This approach provides a durable response, preserving visual function in challenging cases.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...